# A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

> **NCT01587703** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 196 (actual)

## Conditions studied

- Carcinoma, Midline

## Interventions

- **DRUG:** GSK525762

## Key facts

- **NCT ID:** NCT01587703
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-28
- **Primary completion:** 2018-04-13
- **Final completion:** 2019-07-29
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2020-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01587703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01587703, "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01587703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*